Navigation Links
Reportlinker Adds Triple Analysis: Colorectal Cancer, Lung Cancer and Lymphoma
Date:3/24/2011

NEW YORK, March 24, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Triple Analysis: Colorectal Cancer, Lung Cancer and Lymphoma

http://www.reportlinker.com/p0284975/Triple-Analysis-Colorectal-Cancer-Lung-Cancer-and-Lymphoma.html

This triple analysis focuses on cancer drug development strategies in Colorectal Cancer, Lung Cancer and Lymphoma. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Colorectal Cancer

The colorectal cancer report part comprises defined and up to date development strategies for 347 colorectal cancer drugs within the portfolio of 182 investigators, from Ceased to Marketed. This part extensively analyses their 210 identified drug targets, organized into 205 drug target strategies, and assesses them in eight different compound strategies in colorectal cancer.

This part is based on the following publication:

A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market

Part II: Lung Cancer

The lung cancer report part includes defined and up to date development strategies for 283 lung cancer therapeutic drugs (>317 projects) within the portfolio of 167 investigators, from Ceased to Marketed. In total the report assesses three different sub-indications of lung cancer (Non-Small Cell Lung Cancer, Small Cell Lung Cancer and Lung Cancer (general). This report part extensively analyses 182 identified targets of lung cancer drugs, organized into 173 drug target strategies, and assesses them in lung cancer.

This part is based on the following publication:

Competitive Outlook on Lung Cancer Drug Development - The Missing Handbook to New Product Planning and Portfolio Planning

Part III: Lymphoma

The lymphoma report part includes defined and up to date development strategies for 176 lymphoma therapeutic drugs (>230 projects) within the portfolio of 106 investigators, from Ceased to Marketed. In total the report assesses five different sub-indications of lymphoma (B-cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, T-cell lymphoma and Lymphoma (general)). This report part extensively analyses 124 identified targets of lymphoma drugs, organized into 109 drug target strategies, and assesses them in lymphoma.

This part is based on the following publication:

Lymphoma Drug Development Strategies at Work - Define Your Competition

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Colorectal Cancer

5.1 The Scope of this Report 28

6 Consider the Therapeutic Target Among Colorectal Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (210 Drug Targets) 32-451

7 Emerging New Products to Established Ones: Drug Target Strategies of Colorectal Cancer Drugs by their Highest Stage of Development (205 Drug Target Strategies and 347 Colorectal Cancer Drugs) 452-699

8 Compound Strategies at Work: Competitive Benchmarking of Colorectal Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-745

9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Colorectal Cancer Drug Pipeline by Investigator (182 Companies) 746-1,039

10 Disclaimer 1040

11 Drug Index 1041

12 Company Index 1050

Figures: Includes 6 Figures

Tables: Includes 242 Tables

Total Number of Pages: 1,056

Part II: Lung Cancer

5.1 The Scope of this Report 27

6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (182 Drug Targets) 31-323

7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Lung Cancer Pipeline? (173 Drug Target Strategies and 283 Drugs) 324-368

8 Compound Strategies at Work: Competitive Benchmarking of Lung Cancer Pipeline by Type of Compound (7 Different Compound Strategies) 369-419

9 Selecting a Sub-Indication of Lung Cancer for Drug Development 420-462

10 Portfolio Planning: Competitive Benchmarking of Lung Cancer Pipeline by Investigator (167 Investigators) 463-751

12 Drug Index 753

13 Company Index 761

Figures: Includes 13 Figures

Tables: Includes 227 Tables

Total Number of Pages: 596

Part III: Lymphoma

5.1 The Scope of this Report 22

6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment (124 Drug Targets) 26-250

7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Lymphoma Pipeline? (109 Drug Target Strategies and 176 Drugs) 251-280

8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Pipeline by Type of Compound (6 Different Compound Strategies) 281-312

9 Selecting a Sub-Indication of Lymphoma for Drug Development 313-450

10 Portfolio Planning: Competitive Benchmarking of Lymphoma Pipeline by Investigator (106 Investigators) 351-524

12 Drug Index 526

13 Company Index 531

Figures: Includes 17 Figures

Tables: Includes 164 Tables

Total Number of Pages: 535

To order this report:

: Triple Analysis: Colorectal Cancer, Lung Cancer and Lymphoma

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Therapeutics for Immune System Disorders
2. Reportlinker Adds Process Analytical Technologies for Pharmaceuticals: Global Markets
3. Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets
4. Reportlinker Adds Global Vitamins Industry
5. Reportlinker Adds US Medical Adhesives And Sealants Industry
6. Reportlinker Adds Global Microscopes Industry
7. Reportlinker Adds Global Imaging Agents Industry
8. Reportlinker Adds Global Stethoscopes Industry
9. Reportlinker Adds Global Micro-Electromechanical Systems (MEMs) Devices Industry
10. Reportlinker Adds U.K. Market for Dental Prosthetics and CAD/CAM Devices 2011
11. Reportlinker Adds Global Cardiac Monitoring Systems Market -2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017  iCAD (Nasdaq: ICAD), ... solutions and radiation therapy for the early identification ... Tomo Detection received Premarket Approval (PMA) from the ... Detection is a first-of-its-kind, concurrent-read computer aided detection ... the latest innovation available on the PowerLook® Breast ...
(Date:3/27/2017)... 27, 2017  Impax Laboratories, Inc. (NASDAQ: IPXL)today announced ... M. Bisaro as Impax,s President and Chief Executive ... March 27, 2017. Mr. Bisaro will succeed J. ... and Chief Executive Officer since December of 2016. ... pharmaceutical experience, Mr. Bisaro, 56, is an accomplished global ...
(Date:3/27/2017)... March 27, 2017   Genprex, Inc. , a privately held, ... Pham , MD, the Company,s Chief Operating Officer, is scheduled to ... Sachs 5th Annual Cancer BioPartnering & Investment Forum: Tuesday, ... York, NY ... BioCentury 24th Annual Future Leaders in Biotech Industry – ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... March 27, 2017 , ... American ... conference coverage on veterinary medicine, announces the launch of Veterinarian’s Money Digest™, a ... with the April edition of American Veterinarian™. , “We look forward ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... management program at Women’s Excellence will help patients lose weight and keep it ... The specialists at Women's Excellence will measure BMI, body fat composition, and ...
(Date:3/27/2017)... ... March 27, 2017 , ... EpiGentek ... to pursue the recent RNA methylation “gold rush” with their established portfolio of ... newfound characteristics of N6-methyladenosine, or m6A , RNA methylation has received a ...
(Date:3/27/2017)... ... March 27, 2017 , ... The ... supply chain professionals, will hold their first Northeast Regional AHVAP Meeting. For 2017, ... , “Increasingly, supply chain and value analysis professionals have a ‘seat at the ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... According to ... prostate cancer, including all stages, is more than 95%. Once the cancer spreads to ... less than 30%. To find out how to avoid this latter group, tune in ...
Breaking Medicine News(10 mins):